• Multiple Myeloma
    • Robert A Kyle
    • Robert A Kyle: Influence Statistics

      Robert A Kyle

      Robert A Kyle

      Show email address

      Mayo Clinic, Rochester, Minnesota, United States | Division of Hematology, Mayo Clinic, Rochester, MN; | Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Robert A Kyle:Expert Impact

      Concepts for whichRobert A Kylehas direct influence:Multiple myeloma,Undetermined significance,Monoclonal gammopathy,Primary systemic amyloidosis,Bone marrow,Plasma cells,Monoclonal gammopathies,Light chain.

      Robert A Kyle:KOL impact

      Concepts related to the work of other authors for whichfor which Robert A Kyle has influence:Multiple myeloma,Bone marrow,Cardiac amyloidosis,Monoclonal gammopathy,Celiac disease,Undetermined significance,Poems syndrome.

      KOL Resume for Robert A Kyle


      Mayo Clinic, Rochester, Minnesota, United States


      Division of Hematology and

      Department of Medicine, Mayo Clinic, Rochester, MN, USA

      Mayo Clinic Rochester, Rochester, MN


      Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA

      Mayo Clinic Rochester, Division of Hematology, Rochester, MN

      Division of Hematology, and


      Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN USA

      4 Mayo Clinic, Rochester, MN.


      Division of Nephrology, Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN USA

      Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

      Mayo Clinic, Rochester, MN.

      Hematology and.


      Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA


      Department of Laboratory Medicine and Pathology, Mayo Clinic, Minneapolis, MN;

      Divisions of Hematology and Blood and Marrow Transplantation, Mayo Clinic, Rochester, MN

      Amyloidosis Research and Treatment Center, Pavia, Italy


      Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

      Mayo Clinic Department of Internal Medicine Rochester Minnesota


      Department of Hematology, Mayo Clinic, Rochester, Minnesota

      Division of Hematology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA

      Mayo Clinic, 200 First Street SW, Rochester, MN 55905,

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Robert A Kyle is among the top experts in the world.
      Concept World rank
      atn uae #1
      transthyretin leucine #1
      bcg nephelometry #1
      baseline serum samples #1
      18f‐fdg positron emission #1
      cd19 blood #1
      hepatic amyloidosis patients #1
      patients alcrab #1
      4–327 months #1
      recombinant interferon alfa‐2 #1
      24‐h urine monitoring #1
      acquisition del17p #1
      abnormal karyotypes patients #1
      primary systemic #1
      cells prognosis #1
      relatives mm #1
      mgus monoclonal protein #1
      martin kirschner #1
      therapy melphalan #1
      clinical features wm #1
      creatinine≥5 #1
      clonal pcs bm #1
      hicy ifn #1
      dflc increase #1
      mm smm #1
      5 years year #1
      initial therapy mm #1
      improved response rates #1
      transthyretin systemic amyloidosis #1
      hypodiploid myeloma #1
      μ‐heavy chain disease #1
      modern induction regimens #1
      myelomas patients #1
      single agent dexamethasone #1
      evidence multiple myeloma #1
      blood monoclonal #1
      cyclophosphamide hicy #1
      familial myeloma report #1
      plasma cell antigens #1
      igm mm #1
      alpcmm multivariate analysis #1
      patients mipg #1
      philately united #1
      massfix patients #1
      myeloma based #1
      patients secretory myeloma #1
      iga multiple #1
      transplant multiple myeloma #1
      cast nephropathy patients #1
      charlsoncomorbidityindex #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Robert A Kyle

      KOL-Index: 16971

      In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the ...

      Known for Cell Transplantation | Patients Mm | European Society | Clinical Trial | Allogeneic Hct
      KOL-Index: 15129

      BACKGROUND: The detection of monoclonal free light chains (FLCs) is an important diagnostic aid for a variety of monoclonal gammopathies and is especially important in light-chain diseases, such as light-chain myeloma, primary systemic amyloidosis, and light-chain-deposition disease. These diseases are more prevalent in the elderly, and assays to detect and quantify abnormal amounts of FLCs require reference intervals that include elderly donors.

      METHODS: We used an automated immunoassay ...

      Known for Reference Intervals | Immunoglobulin Light | Diagnostic Ranges | Free Κ | Monoclonal Flcs
      KOL-Index: 14785

      Translocations involving immunoglobulin (Ig) loci and chromosome 13 monosomy (Delta 13) are frequent cytogenetic findings in multiple myeloma (MM). Similar chromosomal aberrations have been identified in the monoclonal gammopathy of undetermined significance (MGUS), but their prevalence and significance remain uncertain. Bone marrow from 72 patients with MGUS (n = 62) and smoldering MM (n = 10) was evaluated for translocations between the Ig heavy chain (IgH) and chromosomes 4, 11, and ...

      Known for Human Pair | Undetermined Significance | Mgus Mm | Fibroblast Growth Factor | 13 Chromosomes
      KOL-Index: 13958

      Autologous hematopoietic stem cell transplantation (AHCT) improves survival in patients with multiple myeloma (MM) but is associated with morbidity and nonrelapse mortality (NRM). Hematopoietic cell transplant comorbidity index (HCT-CI) was shown to predict risk of NRM and survival after allogeneic transplantation. We tested the utility of HCT-CI as a predictor of NRM and survival in patients with MM undergoing AHCT. We analyzed outcomes of 1156 patients of AHCT after high-dose melphalan ...

      Known for Cell Transplantation | Multiple Myeloma | Hctci Score | Autologous Hematopoietic | Patients Mm
      KOL-Index: 12816

      Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting ...

      Known for Plasma Exchange | Cast Nephropathy | Free Light Chains | Renal Disease | Multiple Myeloma Treatment
      KOL-Index: 12807

      Myeloma kidney is the major cause of severe irreversible renal failure in patients with multiple myeloma. This tubulointerstitial injury is a direct consequence of high concentrations of circulating monoclonal free light chains (FLCs) produced by a clonal expansion of plasma cells. Early reduction of serum FLCs associates with renal recovery, but the target threshold of reduction to facilitate renal recovery is unknown. To determine the relationship between the achieved FLC reduction and ...

      Known for Renal Recovery | Myeloma Kidney | Light Chains | Flc Reduction | Aged 80
      KOL-Index: 12744

      OBJECTIVES: This study was designed to determine the clinical value of a Doppler-derived index of combined systolic and diastolic myocardial performance in the assessment of cardiac amyloidosis.

      BACKGROUND: Cardiac amyloidosis is an infiltrative disease with diastolic and systolic dysfunction. Therefore, the index of myocardial performance combining systolic and diastolic time intervals could be a useful predictor of clinical outcome in cardiac amyloidosis.

      METHODS: The study included 45 ...

      Known for Diastolic Myocardial | Patients Cardiac Amyloidosis | Combining Systolic | Ejection Time | Isovolumetric Contraction
      KOL-Index: 12662

      BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is defined by expression of heavy-chain immunoglobulin (IgH) and is the precursor lesion for 80% of cases of multiple myeloma. The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS.

      METHODS: We used a population-based cohort, previously assembled to estimate MGUS prevalence, of 21,463 residents of Olmsted County, MN, USA, ...

      Known for Undetermined Significance | Light Chain | Risk Progression | Mgus Prevalence | Monoclonal Gammopathy
      KOL-Index: 12602

      BACKGROUND: Previous studies have indicated that the incidence and mortality rates for multiple myeloma have increased in the United States. The authors reported on the incidence of multiple myeloma in Olmsted County, Minnesota, between 1991 and 2001 and on trends in multiple myeloma incidence over the last 56 years.

      METHODS: Using the files of the Mayo Clinic and the Olmsted Medical Center (Rochester, MN), the authors identified all residents of Olmsted County who had multiple myeloma, ...

      Known for Olmsted County | Multiple Myeloma | Child Child | Aged Minnesota | Undetermined Significance
      KOL-Index: 12409

      MGUS is characterized by the presence of a serum M-protein less than 3 g/dL; fewer than 10% plasma cells in the bone marrow; no, or only small amounts of, M-protein in the urine; absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency; and, most importantly, stability of the M-protein and failure of development of other abnormalities, MGUS is found in approximately 3% of persons older than 70 years and in 1% of those 50 years or older. During long-term follow-up, ...

      Known for Solitary Plasmacytoma | Multiple Myeloma | Mgus Mm | Renal Insufficiency | Bone Marrow
      KOL-Index: 12397

      BACKGROUND: The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) in an attempt to determine which of these regimens should be the standard treatment for multiple myeloma.

      METHODS: Four hundred seventy-nine previously untreated patients with multiple myeloma from 23 ECOG institutions were enrolled. Treatment, assigned by randomization, ...

      Known for Melphalan Prednisone | Patients Vbmcp | Multiple Myeloma | Vincristine Carmustine | 1 Year
      KOL-Index: 12343

      Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of multiple myeloma (MM) is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published medical literature and for grading the quality of the evidence, the strength of the evidence, and the strength of the treatment recommendations. Treatment recommendations based on the evidence presented in the review were made unanimously ...

      Known for Multiple Myeloma | Stem Cell | Cytotoxic Therapy | Treatment Recommendations Evidence | Based Review
      KOL-Index: 12207

      PURPOSE: There is consensus that patients with light chain (AL) amyloidosis with hypercalcemia, renal failure, anemia, and lytic bone lesions attributable to clonal expansion of plasma cells (CRAB criteria) also have multiple myeloma (MM). The aim of this study was to examine the spectrum of immunoglobulin AL amyloidosis with and without MM, with a goal of defining the optimal bone marrow plasma cell (BMPC) number to qualify as AL amyloidosis with MM.

      PATIENTS AND METHODS: We identified ...

      Known for Multiple Myeloma | Patients Amyloidosis | Plasma Cells | Bone Marrow | Immunoglobulin Light

      Key People For Multiple Myeloma

      Top KOLs in the world
      Kenneth Carl Anderson
      multiple myeloma mm cells board directors
      Robert A Kyle
      multiple myeloma undetermined significance consultancy funding
      Sundararajan Vincent Rajkumar
      multiple myeloma consultancy funding undetermined significance
      Paul Gerard Guy Richardson
      multiple myeloma board directors advisory committees
      JesusFernando San San Miguel
      multiple myeloma consultancy honoraria board directors
      Bart Barlogie
      multiple myeloma total therapy gene expression

      Mayo Clinic, Rochester, Minnesota, United States | Division of Hematology, Mayo Clinic, Rochester, MN; | Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA | Hematology, Mayo Clinic, Rochester, Rochester | Division of Hematology, Mayo

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.